The performance of contemporary cystatin C-based GFR equations in predicting gentamicin clearance

British Journal of Clinical Pharmacology

Volumn 79, Issue 2, 2015, Pages 268-277

  Chin, Paul K L ^a   Chew Harris, Janice S C ^b   Florkowski, Christopher M ^c   Begg, Evan J ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b Canterbury Health Laboratories Endolab   (New Zealand)

^c CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

clearance; cystatin C; gentamicin; glomerular filtration rate

Indexed keywords

CYSTATIN C; GENTAMICIN; GLUCOCORTICOID; ANTIINFECTIVE AGENT; CREATININE;

ADULT; AGED; ARTICLE; BODY MASS; BODY SURFACE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG CLEARANCE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THYROID FUNCTION TEST; VOLUME OF DISTRIBUTION; ADOLESCENT; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DOSE RESPONSE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BODY MASS INDEX; CREATININE; CYSTATIN C; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENTAMICINS; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 84941068706     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12501     Document Type: Article

References (45)

1. Chew JS, Saleem M, Florkowski CM, George PM,. Cystatin C-a paradigm of evidence based laboratory medicine. Clin Biochem Rev 2008; 29: 47-62.
2. KDIGO. KDIGO clinical practice guideline for chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150.
3. Sjostrom P, Tidman M, Jones I,. Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand J Clin Lab Invest 2005; 65: 111-124.
4. Grubb AO,. Cystatin C-properties and use as diagnostic marker. Adv Clin Chem 2001; 35: 63-99.
5. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW,. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365-3370.
6. Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C,. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006; 34: 1913-1917.
7. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, Philipp T, Kribben A,. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115-1122.
8. Briguori C, Visconti G, Rivera NV, Focaccio A, Golia B, Giannone R, Castaldo D, De Micco F, Ricciardelli B, Colombo A,. Cystatin C and contrast-induced acute kidney injury. Circulation 2010; 121: 2117-2122.
9. Ribichini F, Gambaro G, Graziani MS, Pighi M, Pesarini G, Pasoli P, Anselmi M, Ferrero V, Yabarek T, Sorio A, Rizzotti P, Lupo A, Vassanelli C,. Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions. Clin Chem 2012; 58: 458-464.
10. Spahillari A, Parikh CR, Sint K, Koyner JL, Patel UD, Edelstein CL, Passik CS, Thiessen-Philbrook H, Swaminathan M, Shlipak MG, Consortium T-A,. Serum cystatin C- versus creatinine-based definitions of acute kidney injury following cardiac surgery: a prospective cohort study. Am J Kidney Dis 2012; 60: 922-929.
11. Avent ML, Rogers BA, Cheng AC, Paterson DL,. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J 2011; 41: 441-449.
12. Begg EJ, Barclay ML,. Aminoglycosides-50 years on. Br J Clin Pharmacol 1995; 39: 597-603.
13. Contrepois A, Brion N, Garaud JJ, Faurisson F, Delatour F, Levy JC, Deybach JC, Carbon C,. Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans. Antimicrob Agents Chemother 1985; 27: 520-524.
14. Zarowitz BJ, Robert S, Peterson EL,. Prediction of glomerular filtration rate using aminoglycoside clearance in critically ill medical patients. Ann Pharmacother 1992; 26: 1205-1210.
15. Pai MP, Rodvold KA,. Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity. Diagn Microbiol Infect Dis 2014; 78: 178-187.
16. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS, Investigators C-E,. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20-29.
17. Schaeffner ES, Ebert N, Delanaye P, Frei U, Gaedeke J, Jakob O, Kuhlmann MK, Schuchardt M, Tolle M, Ziebig R, van der Giet M, Martus P,. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med 2012; 157: 471-481.
18. Chin PK, Florkowski CM, Begg EJ,. The performances of the Cockcroft-Gault, modification of diet in renal disease study and chronic kidney disease epidemiology collaboration equations in predicting gentamicin clearance. Ann Clin Biochem 2013; 50: 546-557.
19. Begg EJ, Barclay ML, Duffull SB,. A suggested approach to once daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605-609.
20. Duffull SB, Kirkpatrick CM, Begg EJ,. Comparison of two Bayesian approaches to dose-individualization for once daily aminoglycoside regimens. Br J Clin Pharmacol 1997; 43: 125-135.
21. Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N,. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet 2013; 52: 9-22.
22. Bjarnadottir M, Grubb A, Olafsson I,. Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest 1995; 55: 617-623.
23. Risch L, Saely C, Reist U, Reist K, Hefti M, Huber AR,. Course of glomerular filtration rate markers in patients receiving high-dose glucocorticoids following subarachnoidal hemorrhage. Clin Chim Acta 2005; 360: 205-207.
24. Jayagopal V, Keevil BG, Atkin SL, Jennings PE, Kilpatrick ES,. Paradoxical changes in cystatin C and serum creatinine in patients with hypo- and hyperthyroidism. Clin Chem 2003; 49: 680-681.
25. Fricker M, Wiesli P, Brandle M, Schwegler B, Schmid C,. Impact of thyroid dysfunction on serum cystatin C. Kidney Int 2003; 63: 1944-1947.
26. Wiesli P, Schwegler B, Spinas GA, Schmid C,. Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta 2003; 338: 87-90.
27. Chew-Harris JS, Florkowski CM, George PM, Elmslie JL, Endre ZH,. The relative effects of fat versus muscle mass on cystatin C and estimates of renal function in healthy young men. Ann Clin Biochem 2013; 50: 39-46.
28. Shlipak MG, Mattes MD, Peralta CA,. Update on cystatin C: incorporation into clinical practice. Am J Kidney Dis 2013; 62: 595-603.
29. Grubb A, Blirup-Jensen S, Lindstrom V, Schmidt C, Althaus H, Zegers I, IFCC Working Group on Standardisation of Cystatin C (WG-SCC). First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin Chem Lab Med 2010; 48: 1619-1621.
30. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J,. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
31. Mosteller RD,. Simplified calculation of body surface area. N Engl J Med 1987; 317: 1098.
32. Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, Townsend R, Okparavero A, Zhang YL, Schmid CH, Levey AS, Chronic Kidney Disease Epidemiology C. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 2009; 54: 33-42.
33. Bland JM, Altman DG,. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
34. Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K,. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012; 156: 785-795.
35. Reinhard M, Erlandsen EJ, Randers E,. Biological variation of cystatin C and creatinine. Scand J Clin Lab Invest 2009; 69: 831-836.
36. Matzke GR, Aronoff GR, Atkinson AJ, Jr, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P,. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int 2011; 80: 1122-1137.
37. van Acker BA, Prummel MF, Weber JA, Wiersinga WM, Arisz L,. Effect of prednisone on renal function in man. Nephron 1993; 65: 254-259.
38. Baxter K,. Stockley's Drug Interactions: A Source Book of Interactions, Their Mechanisms, Clinical Importance and Management. London: Pharmaceutical Press, 2010.
39. Chanson P, Joly V, Contrepois A, Garaud JJ, Bauchet J, Mohler J, Nguyen PC, Carbon C,. Alteration of gentamicin and cefazolin kinetics with control of the hypothyroid state in humans. Antimicrob Agents Chemother 1987; 31: 635-637.
40. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE,. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-1421.
41. Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, Froissart M, Kusek JW, Zhang YL, Coresh J, Levey AS,. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 2009; 75: 652-660.
42. Heaf JG,. The origin of the 1.73-m2 body surface area normalization: problems and implications. Clin Physiol Funct Imaging 2007; 27: 135-137.
43. Howey OK, Chin PK,. Usage of renal function equations to guide prescribing in general medicine. N Z Med J 2013; 126: 97-99.
44. Delanaye P, Mariat C, Cavalier E, Krzesinski JM,. Errors induced by indexing glomerular filtration rate for body surface area: reductio ad absurdum. Nephrol Dial Transplant 2009; 24: 3593-3596.
45. Dooley MJ, Poole SG,. Poor correlation between body surface area and glomerular filtration rate. Cancer Chemother Pharmacol 2000; 46: 523-526.